Allogeneic CARs on the horizon
How orthogonal technologies could make allogeneic cells the future of CAR Ts
With the first generation of autologous, personalized CAR T cell therapies on the market, the field is turning to allogeneic technologies to provide better scale and lower costs. But drug makers are learning that as they solve the first hurdle of graft-versus-host reactions, they need a way to avoid exacerbating the opposite problem, host-versus-graft.
There’s little dispute that while autologous CAR T cells have been transformational for a handful of blood cancers, they represent a sliver of the spectrum of possibilities that the technology might offer. ...